TY - JOUR
T1 - Riociguat treatment for portopulmonary hypertension
T2 - a subgroup analysis from the PATENT-1/-2 studies
AU - Cartin-Ceba, Rodrigo
AU - Halank, Michael
AU - Ghofrani, Hossein Ardeschir
AU - Humbert, Marc
AU - Mattson, John
AU - Fritsch, Arno
AU - Krowka, Michael
N1 - Funding Information:
Medical writing assistance was provided by Adelphi Communications Ltd (Bollington, UK), funded by Bayer AG (Berlin, Germany).
Funding Information:
RC-C has nothing to disclose. MHa reports personal fees (lectures) from Actelion, Bayer AG, GlaxoSmithKline, Merck Sharp & Dohme, and Optimal Medical Therapies (OMT); non-financial support (travel) from Actelion and OMT; and other (advisory board) from Actelion, Bayer AG, and GlaxoSmithKline (GSK), outside the submitted work. H-AG reports grants from DFG (German Research Foundation); honoraria from Actelion, Bayer, Ergonex, Gilead, GSK, Novartis, and Pfizer; consultancy fees from AbbVie, Actelion, Bayer, Bellerophon Pulse Technologies, Ergonex, Gilead, GSK, Medscape, Merck Sharp & Dohme, Novartis, OMT, Pfizer, and Web MD Global; and speaker’s bureau fees from Actelion, Bayer, Ergonex, Gilead, GSK, Novartis, and Pfizer. MHu reports personal fees from Actelion, Arena, Bayer, GSK, Merck, Novartis, Pfizer, and United Therapeutics. JM and AF are full-time employees of Bayer AG. MK reports involvement in the steering committee for the PORTICO trial, supported by Actelion, during the conduct of the study.
Funding Information:
This study was supported by Bayer AG (Berlin, Germany).
PY - 2018/4/1
Y1 - 2018/4/1
N2 - In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.
AB - In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.
KW - portal hypertension
KW - pulmonary arterial hypertension
KW - soluble guanylate cyclase stimulator
UR - http://www.scopus.com/inward/record.url?scp=85049873206&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049873206&partnerID=8YFLogxK
U2 - 10.1177/2045894018769305
DO - 10.1177/2045894018769305
M3 - Letter
AN - SCOPUS:85049873206
VL - 8
JO - Pulmonary Circulation
JF - Pulmonary Circulation
SN - 2045-8932
IS - 2
ER -